Difference between revisions of "Interferon alfa-2b (Intron-A)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m |
||
Line 11: | Line 11: | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
+ | *[[Pancreatic NET]] | ||
*[[Systemic mastocytosis]] | *[[Systemic mastocytosis]] | ||
− | *[[ | + | |
+ | ==Diseases for which it was used== | ||
+ | *[[Follicular lymphoma - obsolete|Follicular lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
Line 75: | Line 78: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
+ | [[Category:Subcutaneous medications]] | ||
+ | [[Category:Intralesional medications]] | ||
+ | [[Category:Intramuscular medications]] | ||
+ | [[Category:Intravenous medications]] | ||
+ | |||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:Cytokines]] | [[Category:Cytokines]] | ||
Line 82: | Line 90: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
+ | [[Category:Pancreatic NET medications]] | ||
[[Category:Systemic mastocytosis medications]] | [[Category:Systemic mastocytosis medications]] | ||
− | |||
[[Category:Drugs FDA approved in 1986]] | [[Category:Drugs FDA approved in 1986]] |
Revision as of 21:01, 22 January 2018
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Melanoma
- Multiple myeloma
- Neuroendocrine tumors
- Pancreatic NET
- Systemic mastocytosis
Diseases for which it was used
Patient drug information
- Interferon alfa-2b (Intron-A) patient drug information (Chemocare)[4]
- Interferon alfa-2b (Intron-A) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/4/1986: Initial FDA approval
Also known as
Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Advaferon | Alfaferone | Berofor | Biogamma | Canferon A | |||
Cytoferon | Egiferon | Feron | Fiblaferon | Frone | |||
Finnferon-Alpha | Heberon Alfa R | Humoferon | IFN Alpha | Imufor | |||
Imukin | INF | Inferax | Infergen | Inmutag | |||
Interfero | Interferon Alfanative | Interferon Human | Interferon Leucocyticum | Interferon Lymphoblastoid | |||
Interferonum Leucocyticum | Laroferon | Multiferon | Namalvin | OIF | |||
Polyferon | Realdiron | Roceron-A | Sumiferon | Wellferon |
References
- Drug index
- Subcutaneous medications
- Intralesional medications
- Intramuscular medications
- Intravenous medications
- Immunotherapy
- Cytokines
- Chronic myelogenous leukemia medications
- Melanoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Pancreatic NET medications
- Systemic mastocytosis medications
- Drugs FDA approved in 1986